Search Results For:
- Issue:
- Business model | Payment Structures
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Industry
Drug
Preclinical
BMGF - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Multilateral organization
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Multilateral organization
Diagnostic
Drug
Vaccine
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[issue] => Array
(
[0] => royalties-and-payments
)
)
[filters] => Array
(
[provision] => Array
(
[issue] => Array
(
[0] => royalties-and-payments
)
)
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => royalties-and-payments
)
)
)
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => royalties-and-payments
)
)
)
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => royalties-and-payments
)
)
)
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[taxonomy] => issue
[term] => royalties-and-payments
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => issue
[terms] => Array
(
[0] => royalties-and-payments
)
[field] => slug
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wpry_term_relationships
)
[queried_terms] => Array
(
[issue] => Array
(
[terms] => Array
(
[0] => royalties-and-payments
)
[field] => slug
)
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT wpry_posts.*
FROM wpry_posts LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
WHERE 1=1 AND (
wpry_term_relationships.term_taxonomy_id IN (70)
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
GROUP BY wpry_posts.ID
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5113
[post_author] => 5
[post_date] => 2022-06-29 13:33:56
[post_date_gmt] => 2022-06-29 13:33:56
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 13:36:36
[post_modified_gmt] => 2022-06-29 13:36:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4864
[post_author] => 5
[post_date] => 2022-06-07 08:29:48
[post_date_gmt] => 2022-06-07 08:29:48
[post_content] =>
[post_title] => Boston University Startup Exclusive License Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => boston-university-startup-exclusive-license-template-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-07 08:44:05
[post_modified_gmt] => 2022-06-07 08:44:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4864
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4842
[post_author] => 5
[post_date] => 2022-05-31 08:33:58
[post_date_gmt] => 2022-05-31 08:33:58
[post_content] =>
[post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 08:33:58
[post_modified_gmt] => 2022-05-31 08:33:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4842
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4684
[post_author] => 5
[post_date] => 2022-04-25 12:25:07
[post_date_gmt] => 2022-04-25 12:25:07
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:13:09
[post_modified_gmt] => 2022-04-26 15:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4684
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4483
[post_author] => 5
[post_date] => 2022-03-17 13:21:19
[post_date_gmt] => 2022-03-17 13:21:19
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 13:22:33
[post_modified_gmt] => 2022-03-17 13:22:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4483
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:54:54
[post_modified_gmt] => 2022-05-31 17:54:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4063
[post_author] => 5
[post_date] => 2022-01-07 10:34:51
[post_date_gmt] => 2022-01-07 10:34:51
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 10:34:51
[post_modified_gmt] => 2022-01-07 10:34:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4063
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:53:55
[post_modified_gmt] => 2022-05-27 08:53:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3722
[post_author] => 5
[post_date] => 2021-08-23 12:12:50
[post_date_gmt] => 2021-08-23 12:12:50
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 12:14:33
[post_modified_gmt] => 2021-08-23 12:14:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3722
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3698
[post_author] => 5
[post_date] => 2021-08-19 14:33:22
[post_date_gmt] => 2021-08-19 14:33:22
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 19:16:34
[post_modified_gmt] => 2022-01-18 19:16:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3698
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:46:20
[post_modified_gmt] => 2022-05-27 08:46:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3691
[post_author] => 5
[post_date] => 2021-08-18 09:29:08
[post_date_gmt] => 2021-08-18 09:29:08
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:09:07
[post_modified_gmt] => 2021-12-03 12:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3691
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:24:35
[post_modified_gmt] => 2022-02-28 08:24:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3346
[post_author] => 6
[post_date] => 2021-06-30 13:07:59
[post_date_gmt] => 2021-06-30 13:07:59
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-01 14:01:02
[post_modified_gmt] => 2022-06-01 14:01:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3346
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3315
[post_author] => 6
[post_date] => 2021-06-30 10:19:01
[post_date_gmt] => 2021-06-30 10:19:01
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 10:19:01
[post_modified_gmt] => 2021-06-30 10:19:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3312
[post_author] => 6
[post_date] => 2021-06-30 10:06:34
[post_date_gmt] => 2021-06-30 10:06:34
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:00:53
[post_modified_gmt] => 2021-08-23 10:00:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3312
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 12:12:41
[post_modified_gmt] => 2022-05-24 12:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 1117
[post_author] => 6
[post_date] => 2020-05-21 21:17:31
[post_date_gmt] => 2020-05-21 21:17:31
[post_content] =>
[post_title] => MPP – University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-university-of-liverpool
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:20:41
[post_modified_gmt] => 2021-12-07 11:20:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 33
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5113
[post_author] => 5
[post_date] => 2022-06-29 13:33:56
[post_date_gmt] => 2022-06-29 13:33:56
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 13:36:36
[post_modified_gmt] => 2022-06-29 13:36:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 33
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] => 1
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 30a4d2e511bd2262c3a17ae37ef53bd5
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 5113
[post_author] => 5
[post_date] => 2022-06-29 13:33:56
[post_date_gmt] => 2022-06-29 13:33:56
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 13:36:36
[post_modified_gmt] => 2022-06-29 13:36:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4864
[post_author] => 5
[post_date] => 2022-06-07 08:29:48
[post_date_gmt] => 2022-06-07 08:29:48
[post_content] =>
[post_title] => Boston University Startup Exclusive License Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => boston-university-startup-exclusive-license-template-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-07 08:44:05
[post_modified_gmt] => 2022-06-07 08:44:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4864
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4842
[post_author] => 5
[post_date] => 2022-05-31 08:33:58
[post_date_gmt] => 2022-05-31 08:33:58
[post_content] =>
[post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 08:33:58
[post_modified_gmt] => 2022-05-31 08:33:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4842
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4684
[post_author] => 5
[post_date] => 2022-04-25 12:25:07
[post_date_gmt] => 2022-04-25 12:25:07
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:13:09
[post_modified_gmt] => 2022-04-26 15:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4684
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4483
[post_author] => 5
[post_date] => 2022-03-17 13:21:19
[post_date_gmt] => 2022-03-17 13:21:19
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 13:22:33
[post_modified_gmt] => 2022-03-17 13:22:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4483
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:54:54
[post_modified_gmt] => 2022-05-31 17:54:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4063
[post_author] => 5
[post_date] => 2022-01-07 10:34:51
[post_date_gmt] => 2022-01-07 10:34:51
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 10:34:51
[post_modified_gmt] => 2022-01-07 10:34:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4063
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:53:55
[post_modified_gmt] => 2022-05-27 08:53:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3722
[post_author] => 5
[post_date] => 2021-08-23 12:12:50
[post_date_gmt] => 2021-08-23 12:12:50
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 12:14:33
[post_modified_gmt] => 2021-08-23 12:14:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3722
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3698
[post_author] => 5
[post_date] => 2021-08-19 14:33:22
[post_date_gmt] => 2021-08-19 14:33:22
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 19:16:34
[post_modified_gmt] => 2022-01-18 19:16:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3698
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:46:20
[post_modified_gmt] => 2022-05-27 08:46:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3691
[post_author] => 5
[post_date] => 2021-08-18 09:29:08
[post_date_gmt] => 2021-08-18 09:29:08
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:09:07
[post_modified_gmt] => 2021-12-03 12:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3691
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:24:35
[post_modified_gmt] => 2022-02-28 08:24:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3346
[post_author] => 6
[post_date] => 2021-06-30 13:07:59
[post_date_gmt] => 2021-06-30 13:07:59
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-01 14:01:02
[post_modified_gmt] => 2022-06-01 14:01:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3346
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3315
[post_author] => 6
[post_date] => 2021-06-30 10:19:01
[post_date_gmt] => 2021-06-30 10:19:01
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 10:19:01
[post_modified_gmt] => 2021-06-30 10:19:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3312
[post_author] => 6
[post_date] => 2021-06-30 10:06:34
[post_date_gmt] => 2021-06-30 10:06:34
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:00:53
[post_modified_gmt] => 2021-08-23 10:00:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3312
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 12:12:41
[post_modified_gmt] => 2022-05-24 12:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 1117
[post_author] => 6
[post_date] => 2020-05-21 21:17:31
[post_date_gmt] => 2020-05-21 21:17:31
[post_content] =>
[post_title] => MPP – University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-university-of-liverpool
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:20:41
[post_modified_gmt] => 2021-12-07 11:20:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] => 1
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 8
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 50
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 32
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 23
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 35
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 51
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 41
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 23
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 54
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 44
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 33
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 22
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 34
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 27
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 27
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 38
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 19
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 36
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 35
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 20
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 8
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 50
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 32
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 23
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 35
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 51
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 41
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 23
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[license-grants] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 54
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[ownership-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 44
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 33
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 22
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 34
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 27
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 27
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 38
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 19
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 36
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 35
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 20
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
[0] => royalties-and-payments
)
)
